Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2011

01-06-2011 | Review

Renal co-morbidity in patients with rheumatic diseases

Authors: Hans-Joachim Anders, Volker Vielhauer

Published in: Arthritis Research & Therapy | Issue 2/2011

Login to get access

Abstract

Renal co-morbidity is common in patients with rheumatic disease based on regular assessment of serum and urine parameters of renal function. When patients present with both arthritis and renal abnormalities the following questions have to be addressed. Is kidney disease a complication of rheumatic disease or its management, or are they both manifestations of a single systemic autoimmune disease? Is rheumatic disease a complication of kidney disease and its management? How do rheumatic disease and kidney disease affect each other even when they are unrelated? The present review provides an overview of how to address these questions in daily practice.
Appendix
Available only for authorised users
Literature
1.
Hill AJ, Thomson RJ, Hunter JA, Traynor JP: The prevalence of chronic kidney disease in rheumatology outpatients. Scott Med J. 2009, 54: 9-12. 10.1258/rsmsmj.54.2.9.CrossRefPubMed
2.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39 (2 Suppl 1): S1-S266.
3.
Anders HJ, Rihl M, Loch O, Schattenkirchner M: Prediction of creatinine clearance from serum creatinine in patients with rheumatoid arthritis: comparison of six formulae and one nomogram. Clin Rheumatol. 2000, 19: 26-29. 10.1007/s100670050006.CrossRefPubMed
4.
Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M: Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol. 2002, 8: 130-133. 10.1097/00124743-200206000-00002.CrossRefPubMed
5.
Kasitanon N, Fine DM, Haas M, Magder LS, Petri M: Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations. Lupus. 2007, 16: 887-895. 10.1177/0961203307084167.CrossRefPubMed
6.
Siedner MJ, Christopher-Stine L, Astor BC, Gelber AC, Fine DM: Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists. J Rheumatol. 2007, 34: 973-977.PubMed
7.
Siedner MJ, Gelber AC, Rovin BH, McKinley AM, Christopher-Stine L, Astor B, Petri M, Fine DM: Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. J Rheumatol. 2008, 35: 84-90.PubMed
8.
Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983, 309: 1543-1546. 10.1056/NEJM198312223092503.CrossRefPubMed
9.
Salesi M, Karimifar M, Farajzadegan Z, Esalatmanesh K, Khosravi S, Fallahi P, Akbarian M: The protein-creatinine ratio in spot morning urine samples and 24-h urinary protein excretion in patients with systemic lupus erythematosus. Rheumatol Int. 2009, 29: 503-507. 10.1007/s00296-008-0742-1.CrossRefPubMed
10.
Leung YY, Szeto CC, Tam LS, Lam CW, Li EK, Wong KC, Yu SW, Kun EW: Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology (Oxford). 2007, 46: 649-652.CrossRef
11.
Koseki Y, Terai C, Moriguchi M, Uesato M, Kamatani N: A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001, 60: 327-331. 10.1136/ard.60.4.327.CrossRefPubMed
12.
Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford). 2008, 47: 350-354.CrossRef
13.
Helin HJ, Korpela MM, Mustonen JT, Pasternack AI: Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 242-247. 10.1002/art.1780380213.CrossRefPubMed
14.
Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, Kuroda T, Sato T, Maruyama Y, Arakawa M: Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998, 50: 154-160.PubMed
15.
Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Kautiainen H, Hakala M: Steep decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol. 2009, 38: 403-
16.
Scott DG, Bacon PA, Elliott PJ, Tribe CR, Wallington TB: Systemic vasculitis in a district general hospital 1972-1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med. 1982, 51: 292-311.PubMed
17.
Scott DG, Bacon PA: Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984, 76: 377-384. 10.1016/0002-9343(84)90654-5.CrossRefPubMed
18.
Sihvonen S, Korpela M, Mustonen J, Laippala P, Pasternack A: Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract. 2004, 96: c107-c114. 10.1159/000077372.CrossRefPubMed
19.
Vilar MJ, Cury SE, Ferraz MB, Sesso R, Atra E: Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol. 1997, 26: 19-23. 10.3109/03009749709065659.CrossRefPubMed
20.
Alenius GM, Stegmayr BG, Dahlqvist SR: Renal abnormalities in a population of patients with psoriatic arthritis. Scand J Rheumatol. 2001, 30: 271-274. 10.1080/030097401753180345.CrossRefPubMed
21.
Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, Orfanos CE: Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997, 77: 305-308.PubMed
22.
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004, 15: 241-250. 10.1097/01.ASN.0000108969.21691.5D.CrossRefPubMed
23.
Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM: Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol. 2007, 34: 332-335.PubMed
24.
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992, 116: 488-498.CrossRefPubMed
25.
de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009, 150: 670-680.CrossRefPubMed
26.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18: 2180-2188. 10.1681/ASN.2007010090.CrossRefPubMed
27.
Medvedev G, Al-Shamari AE, Copland MA, Magil AB: Isolated renal giant cell arteritis. Am J Kidney Dis. 2002, 40: 658-661. 10.1053/ajkd.2002.34931.CrossRefPubMed
28.
Bakkaloglu SA, Ekim M, Tumer N, Tulunay O, Ozer T: Severe renal impairment in the case of classic polyarteritis nodosa. Pediatr Nephrol. 2001, 16: 148-150. 10.1007/s004670000496.CrossRefPubMed
29.
Penn H, Denton CP: Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol. 2008, 20: 692-696. 10.1097/BOR.0b013e3283108df7.CrossRefPubMed
30.
Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D: MPO-ANCA-positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease?. Am J Kidney Dis. 1999, 33: e3-CrossRefPubMed
31.
Muther RS, McCarron DA, Bennett WM: Renal manifestations of sarcoidosis. Arch Intern Med. 1981, 141: 643-645. 10.1001/archinte.141.5.643.CrossRefPubMed
32.
Singer FR, Adams JS: Abnormal calcium homeostasis in sarcoidosis. N Engl J Med. 1986, 315: 755-757. 10.1056/NEJM198609183151209.CrossRefPubMed
33.
Rajakariar R, Sharples EJ, Raftery MJ, Sheaff M, Yaqoob MM: Sarcoid tubulointerstitial nephritis: long-term outcome and response to corticosteroid therapy. Kidney Int. 2006, 70: 165-169. 10.1038/sj.ki.5001512.CrossRefPubMed
34.
Göbel U, Kettritz R, Schneider W, Luft F: The protean face of renal sarcoidosis. J Am Soc Nephrol. 2001, 12: 616-623.PubMed
35.
Birkeland SA, Storm HH: Glomerulonephritis and malignancy: a population-based analysis. Kidney Int. 2003, 63: 716-721. 10.1046/j.1523-1755.2003.00771.x.CrossRefPubMed
36.
Racanelli V, Prete M, Minoia C, Favoino E, Perosa F: Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008, 7: 352-358. 10.1016/j.autrev.2008.02.001.CrossRefPubMed
37.
Abu-Romeh SH, Johny KV: The erythrocyte sedimentation rate in end-stage renal disease [letter]. Am J Kidney Dis. 1988, 12: 169-CrossRefPubMed
38.
Liverman PC, Tucker FL, Bolton WK: Erythrocyte sedimentation rate in glomerular disease: association with urinary protein. Am J Nephrol. 1988, 8: 363-367. 10.1159/000167618.CrossRefPubMed
39.
Kim RP: The musculoskeletal complications of diabetes. Curr Diab Rep. 2002, 2: 49-52. 10.1007/s11892-002-0057-7.CrossRefPubMed
40.
Miller PD: Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol. 2009, 29: 144-155. 10.1016/j.semnephrol.2009.01.007.CrossRefPubMed
41.
Gaffo AL, Saag KG: Management of hyperuricemia and gout in CKD. Am J Kidney Dis. 2008, 52: 994-1009. 10.1053/j.ajkd.2008.07.035.CrossRefPubMed
42.
So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007, 9: R28-10.1186/ar2143.CrossRefPubMed
43.
Announ N, Palmer G, Guerne PA, Gabay C: Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009, 76: 424-426. 10.1016/j.jbspin.2009.01.001.CrossRefPubMed
44.
De Angelis S, Noce A, Di Renzo L, Cianci R, Naticchia A, Giarrizzo GF, Giordano F, Tozzo C, Splendiani G, De Lorenzo A: Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. Eur Rev Med Pharmacol Sci. 2007, 11: 179-184.PubMed
45.
Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F: Recent progress in understanding dialysis-related amyloidosis. Bone. 2009, 45 (Suppl 1): S39-S42.CrossRefPubMed
46.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004, 164: 659-663. 10.1001/archinte.164.6.659.CrossRefPubMed
47.
Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005, 16: 489-495. 10.1681/ASN.2004030203.CrossRefPubMed
48.
National Kidney Foundation: K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003, 41 (4 Suppl 3): I-IV. S1-S91
49.
National Kidney Foundation: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004, 43 (5 Suppl 1): S1-S290.
50.
National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007, 49 (2 Suppl 2): S12-S154.
51.
Abboud H, Henrich WL: Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010, 362: 56-65. 10.1056/NEJMcp0906797.CrossRefPubMed
52.
Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999, 106: 13S-24S. 10.1016/S0002-9343(99)00113-8.CrossRefPubMed
53.
Hörl WH: Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals. 2010, 3: 2291-2321. 10.3390/ph3072291.CrossRef
54.
Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992, 326: 1654-1660. 10.1056/NEJM199206183262502.CrossRefPubMed
55.
Panayi GS, Tugwell P: The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol. 1997, 36: 808-811. 10.1093/rheumatology/36.7.808.CrossRefPubMed
56.
Cush JJ, Tugwell P, Weinblatt M, Yocum D: US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol. 1999, 26: 1176-1186.PubMed
57.
Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 272-276. 10.1002/art.1780390214.CrossRefPubMed
58.
Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK: Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol. 2009, 15: 177-180. 10.1097/RHU.0b013e3181a61f2d.CrossRefPubMed
59.
Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM: Drug Prescribing in Renal Failure. Dosing Guidelines for Adults. 1999, Philadelphia, PA: American College of Physicians-American Society of Internal Medicine, 4
60.
Swarup A, Sachdeva N, Schumacher HR: Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol. 2004, 10: 190-204. 10.1097/01.rhu.0000135555.83088.a2.CrossRefPubMed
61.
National Kidney Foundation: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007, 50: 471-530.CrossRef
62.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009, 113: S1-S130.
63.
Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR: Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009, 53: 617-627. 10.1053/j.ajkd.2008.08.033.CrossRefPubMed
64.
Bardin T, Richette P: Nephrogenic systemic fibrosis. Curr Opin Rheumatol. 2010, 22: 54-58. 10.1097/BOR.0b013e328333bf3d.CrossRefPubMed
Metadata
Title
Renal co-morbidity in patients with rheumatic diseases
Authors
Hans-Joachim Anders
Volker Vielhauer
Publication date
01-06-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3256

Other articles of this Issue 2/2011

Arthritis Research & Therapy 2/2011 Go to the issue

Research article

Associations between the HLA-Apolymorphism and the clinical manifestations of Behcet's disease

Review

Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities

Editorial

Knee osteoarthritis, lumbar-disc degeneration and developmental dysplasia of the hip - an emerging genetic overlap

Research article

Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis

Review

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis

Research article

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits